Crossmark

Understanding Cancer Cachexia and Its Implications in Upper Gastrointestinal Cancers

Published Online: 2022-10-21

Published Print: 2022-12

Authors

Brown, Leo R. https://orcid.org/0000-0001-6181-7020
Laird, Barry J. A.

Wigmore, Stephen J.

Skipworth, Richard J. E.
License Information

Text and Data Mining valid from 2022-10-21

Version of Record valid from 2022-10-21
More Information

Article History

Accepted: 9 October 2022

First Online: 21 October 2022

Declarations

:

: Leo R. Brown declares that he has no conflict of interest. Barry J.A. Laird has received consulting fees from Actimed Therapeutics, Faraday Pharmaceuticals, Kyowa Kirin International, Grunenthal and Artelo Biosciences. He also sits on the advisory board for Actimed Therapeutics and Artelo Biosciences. Stephen J. Wigmore declares that he has no conflict of interest. Richard J.E. Skipworth has received consulting fees from Avidity Biosciences, Faraday Pharmaceuticals, Actimed Therapeutics and Helsinn Healthcare. He has also received conference funding from Helsinn Healthcare and sits on the advisory board for Actimed Therapeutics and Helsinn Healthcare.

: This article does not contain any studies with human/animal subjects performed by any of the authors.

Document is current